CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary

Published:2017-12 Issue: Volume:56 Page:282-289
ISSN:1382-6689
Container-title:Environmental Toxicology and Pharmacology
language:en
Short-container-title:Environmental Toxicology and Pharmacology

Author:

Varnai Reka,Sipeky Csilla,Nagy Lajos,Balogh Sandor,Melegh Bela

Funder

Hungarian National Science Foundation

Publisher

Elsevier BV

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,General Medicine

Reference35 articles.

1. Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients;Apostolakis;J. Am. Coll. Cardiol.,2013

2. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity;Bodin;Blood,2005

3. An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease;Borobia;PLoS One,2012

4. An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease;Borobia;PLoS One,2012

5. Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients receiving warfarin;Burgess;J. Thromb. Haemost.,2013

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case‐cohort;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-04-30

2. Association of VKORC1 polymorphisms and major bleedings in patients who are treated with vitamin K antagonists;Journal of Internal Medicine;2022-09-20

3. The impact of CYP2C9 and VKORC1 genetic polymorphisms in anticoagulant therapy management after cardiac surgery with extracorporeal circulation;Pharmacia;2021-02-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3